Medical devices, healthcare technology and the business of care
510(k) clearance · K254168

Actolind (06.3637. Actolind Gel Plus)

ACTO GmbH · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONK254168

What did the FDA decide?

ACTO GmbH received FDA 510(k) clearance K254168 on September 22, 2026, for Actolind® Gel Plus, a clear, colorless hydrogel whose basis formulation includes Poloxamer 188, monopropylene glycol, hydroxypropyl guar, ammonium lactate, ColaLipid C and purified water, with polyhexamethylenebiguanide HCl at 0.1% w/w as a preservative. The decision was substantially equivalent (SESE), which is a marketing clearance, not a premarket approval. The submission was received December 23, 2025, and the product code is FRO; the FDA page lists the classification name as Dressing, Wound, Drug and the review panel as General & Plastic Surgery.

The summary names Prontosan Wound Gel (B. Braun Medical, K163430, May 23, 2017) as the predicate and states that the chemical-formula differences raise no new or different questions of safety or effectiveness. The indications cover over-the-counter use on minor cuts, abrasions, lacerations and burns, and professional use on ulcers, first- and superficial partial-thickness burns, partial and full thickness wounds, large surface area wounds and surgical incisions. The summary reports ISO 10993 biocompatibility testing and limits use to under 24 hours. The specialty field is recorded as unknown, and no clinical outcome data are provided.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Unknown
Decision date
Sep 22, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K254168
Regulatory pathway
510(k) premarket notification
Applicant
ACTO GmbH
Product code
FRO
Decision code
SESE
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Dressing, Wound, Drug.

Applicant
ACTO GmbH
Product code
FRO
FDA device class
U

FDA decision timeline

  1. K254168 received

    Application receipt date recorded by FDA.

  2. K254168 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code FRO

Product / regulatory recordCompanyPathwayDecision dateSource
Coloplast Corp.510(k) clearanceOct 26, 2026FDA
Magic Science Supply, LLC510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ACTO GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Braunschweig

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records